Harmony Healthcare Fund

The Harmony Healthcare Fund is an open-end equity fund looking for Chinese healthcare companies that are undervalued in overseas securities markets and have sustainable high growth potential. Through strategic consulting and resource injection, we help companies quickly create value and grow into leaders in the medical subsectors. 


Harmony Healthcare Fund was awarded by AsiaHedge in Oct 2018 as the World's Best Small Fund.

Harmony Healthcare Fund was awarded by BarclayHedge in Dec 2019 as Top Performing Hedge Fund. 

Harmony Healthcare Fund was awarded by BarclayHedge in Sep 2019 as No. 3 Net Return under Healthcare/Biotech sector.

Harmony Healthcare Fund was awarded by BarclayHedge in Oct  2019 as No. 2 Net Return under Healthcare/Biotech sector. 

Harmony Healthcare Fund was awarded by BarclayHedge in Jan  2020 as No. 1 Net Return under Healthcare/Biotech sector. 











Investment cases


Grand Pharma (00512.HK): Leader in ophthalmology, ENT and emergency cardiovascular drugs in China,proactive layout of three global innovation tracks, including precision interventional therapy, radionuclide coupled drugs (RDC) and immunotherapy.


Modern Dental (03600.HK): The world's largest manufacturer of dental equipment such as dentures, orthodontics and implants.


Essex Pharma (01061.HK): A biotech leader in ophthalmology, dermatology, and surgical treatments.

BACK

       ©2018 DM Capital Ltd. All rights reserved